Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery

Sponsor
University of Minnesota (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06023329
Collaborator
(none)
36
1
2
15
2.4

Study Details

Study Description

Brief Summary

Literature on the use of superficial cervical plexus blocks for ear surgery is sparse in general, and almost non-existent in the pediatric population. Overall, literature review supports the safety of performance of this block but there is minimal published literature on its utility despite anecdotal evidence of benefit. This study, especially its prospective randomized nature will allow for expansion of the evidence for or against addition of this block to the care of pediatric patients undergoing ear surgery. The purpose of this study is to determine if SCPB plus standard practices provides superior pain control, as measured by reduced opiate consumption, compared to standard practices alone when performed on pediatric patients undergoing surgery on the ear and mastoid process.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group1

Drug: ropivacaine
will receive SCPB with ropivacaine via regional anesthesia team

Placebo Comparator: Group 2

Drug: Saline
will receive SCPB with saline via regional anesthesia team

Outcome Measures

Primary Outcome Measures

  1. Opioid use [30 days post surgery]

    measured on a MME per kilogram

Secondary Outcome Measures

  1. intraoperative opiate use [30 days post surgery]

    Assessed via chart review of opiate administration on an MME basis

  2. post-operative opiate use [30 days post surgery]

  3. Pain level [30 days post surgery]

    Pain level will be assessed via total pain scores via either FLACC or Wong-Baker Faces, both are pain scales from 0-10, 0 being no pain and 10 being the worst pain imaginable. These scales are interchangeable and will allow both patients who can read and younger patients who cannot read to rate their pain.

  4. Quality of Recovery [30 days post surgery]

    Assessed via modified version of the quality of recovery survey. The quality of recovery scale is a validated document for assessing recovery after surgery. The study will use a modified version of this with language changed for parental assessment of Quality of recovery, but the same questions and scale are used.

  5. Post Anesthesia Care Unit anti-emetic use [30 days post surgery]

    Assessed via chart review of post-operative care unit medication administration

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Months to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age: <18 years and >3 months

  • Surgical procedure: Unilateral cochlear implant or tympanomastoidectomy

Exclusion Criteria:
  • Preoperative opiate use within the last 30 days

  • Bilateral surgery

  • No English speaking caregiver

  • Parental/patient refusal

  • Severe preoperative respiratory compromise

  • Allergy to ropivacaine

  • Coagulopathy: Defined by INR>1.5 or Platelet count <100k

  • Current Infection at site of injection

  • VP Shunt on side of surgical procedure

  • Pregnant patients: determined by patient history and available laboratory data. Patients will not be required to have pregnancy testing done if not otherwise indicated.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Minnesota Minneapolis Minnesota United States 55455

Sponsors and Collaborators

  • University of Minnesota

Investigators

  • Principal Investigator: Benjamin Fuller, MD, University of Minnesota

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Minnesota
ClinicalTrials.gov Identifier:
NCT06023329
Other Study ID Numbers:
  • CPB
First Posted:
Sep 5, 2023
Last Update Posted:
Sep 5, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 5, 2023